Camillo Guglielmo Porta, MD, University of Bari Aldo Moro, Bari, Italy, provides an overview of the Phase III CLEAR trial (NCT02811861) of lenvatinib in combination with pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (aRCC). Longer follow-up data and additional efficacy and safety data will be presented that will affirm lenvatinib plus pembrolizumab as first-line therapy for aRCC. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.